Amylyx Pharmaceuticals(us:AMLX)
3.43
-2.28%
Updated on 2025-04-04
Open:3.32
Close:3.43
High:3.56
Low:3.32
Prev Close:3.51
Volume:914162.00
Turnover:3.13M
Turnover Ratio:1.03%
Shares:88.60M
MarketCap:303.91M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 169 | 43627495 | 64.08% | 31 | 29 | 95 |
| 2024-03-31 | 198 | 49502392 | 72.82% | 25 | 56 | 105 |
| 2023-12-31 | 204 | 60278801 | 89.03% | 36 | 79 | 74 |
| 2023-09-30 | 181 | 58909931 | 87.27% | 34 | 68 | 62 |
| 2023-06-30 | 170 | 54430869 | 80.81% | 29 | 66 | 63 |
| 2023-03-31 | 167 | 51250947 | 76.38% | 38 | 59 | 60 |
| 2022-12-31 | 140 | 48578425 | 73.04% | 47 | 49 | 40 |
| 2022-09-30 | 109 | 37440504 | 63.96% | 32 | 38 | 35 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 5348139 | 7.87% | 72573 | 1.38% |
| 2024-03-31 | Blackrock Inc. | 4474722 | 6.58% | 472388 | 11.80% |
| 2024-03-31 | Goldman Sachs Group Inc | 2943186 | 4.33% | 1686325 | 134.17% |
| 2024-03-31 | Millennium Management Llc | 2471455 | 3.64% | 198812 | 8.75% |
| 2024-03-31 | Morgan Stanley | 2070653 | 3.05% | -759590 | -26.84% |
| 2024-03-31 | State Street Corp | 2060042 | 3.03% | 618640 | 42.92% |
| 2024-03-31 | Franklin Resources Inc | 1855886 | 2.73% | 530885 | 40.07% |
| 2024-03-31 | Boxer Capital, Llc | 1500000 | 2.21% | 1500000 | |
| 2024-03-31 | Two Sigma Investments, Lp | 1432865 | 2.11% | 1389065 | 3171.38% |
| 2024-03-31 | Citadel Advisors Llc | 1330384 | 1.96% | -910501 | -40.63% |
About
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Address:43 Thorndike Street
Website:http://www.amylyx.com
Market Movers